Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials
This NMA indicated that aflibercept 8 mg required significantly fewer injections while maintaining similar efficacy over 2 years of treatment compared with faricimab T&E in patients with DME or nAMD.
Authors
- Steven Sherman (ORCID: https://orcid.org/0000-0002-8608-6575)
- Ali Mojebi (ORCID: https://orcid.org/0000-0003-2318-8627)
- Theodore Leng (ORCID: https://orcid.org/0000-0002-8461-3562)
- Andreas Kuznik (ORCID: https://orcid.org/0000-0002-8634-8360)
- Nimesh Patel (ORCID: https://orcid.org/0000-0002-6021-9421)
- Yingxin Xu
- Sam Keeping (ORCID: https://orcid.org/0000-0001-6159-1295)
- Scott M. Friedman
- Keith Chan
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- Palo Alto University (US)
- Regeneron (United States) (US)
- California Retina Consultants (US)
- MD Precision (Canada) (CA)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1007/s40123-025-01247-3
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41